Xcout Intelカイオム・バイオサイエンス competitors & alternatives
The 12 closest competitors and alternatives to カイオム・バイオサイエンス among biotech companies — ranked by similarity to what カイオム・バイオサイエンス actually does, not by market-cap band.
Subscribe to see カイオム・バイオサイエンス’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About カイオム・バイオサイエンス
Chiome Bioscience Inc. engages in the research and development of drug discovery technology platforms worldwide. It operates in two segments, Drug Discovery Business and Drug Discovery Support Business. The company offers ADLib System, a technology for generating monoclonal antibodies which is used to generate antibodies for drug discovery research; and Human ADLib System, which converts chicken antibody genes to humanized antibodies. It also provides protein expression and purification services; stable cell line development services for recombinant protein and antibody production; and antibody generation services using the ADLib system. In addition, the company's product pipeline under Phase 1 trial comprises ADCT-701, an anti-dlk1 antibody for treating liver cancer; CBA-1205, an afucosylated anti-dlk1 antibody for liver cancer, lung cancer, and neuroblastoma; and CBA-1535, an anti 5T4/WAIF1 antibody for malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and triple negative breast cancer (TNBC). Further, its product pipeline under preclinical study includes PCDC, an anti- CDCP1 antibody for lung, colorectal, pancreatic, breast, and ovarian tumors; PTRY, an antibody 5T4/CD3/PD-L1 for treating malignant mesothelioma, small cell lung cancer, non-small cell lung cancer, and TNBC; BMAA, an anti-semphorin3a antibody for treating renal and other diseases; LIV-2008/2008b, an anti-TROP-2 antibody for the treatment of TNBC, lung cancer, and colorectal cancer; PFKR, an anti-CX3CR1 antibody for secondary progressive multiple sclerosis; and PXLR, an anti-CXCL1/2/3/5 antibody for the treatment of gastric, breast, and ovarian tumors. Chiome Bioscience Inc. was incorporated in 2005 and is headquartered in Tokyo, Japan.
カイオム・バイオサイエンス at a glance
カイオム・バイオサイエンス is a biotech company headquartered in Tokyo, Japan. It is publicly listed (4583) with a market capitalisation of $39.7M. Xcout tracks 7 named people at カイオム・バイオサイエンス, including Masamichi Koike (President & CEO).
カイオム・バイオサイエンス leadership
- Masamichi KoikePresident & CEO
- Arihiko BijohiraDirector & Executive Vice President, Chief Operating Officer & Chief Strategy Officer
- Shose TaokaExecutive Director, Head of Development Division
- Hiroyuki KawaiExecutive Director
- Akiyuki FuruyaAudit & Supervisory Committee Member
- Niro SakamotoAudit & Supervisory Committee Member
1 more named person on record for カイオム・バイオサイエンス, with roles, board committees and tenure — see the full roster →
Top 12 カイオム・バイオサイエンス competitors
Ranked by semantic similarity — how close each company is to カイオム・バイオサイエンス by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Biotechnology
Perseus Proteomics Inc. is a Japanese biotechnology company focused on antibody drug discovery and research support. The firm develops novel therapeutic antibody drugs for cancer and other diseases utilizing its proprietary antibody technologies.
Biotechnology
Chimagen Biosciences is a biopharmaceutical company headquartered in Shanghai, China, founded in July 2016. The company specializes in multi-specific antibody therapeutics and built the proprietary TRIAD platform for engineering.
Similar biotech company
Carna Biosciences, Inc., established in Kobe, Japan in 2003, operates as a clinical-stage biopharmaceutical company. Its core focus is on discovering and developing novel drug treatments for significant unmet medical needs, particularly within the Japanese market. In addition to its drug discovery efforts, Carna Biosciences offers an array of specialized research tools. These comprise diverse kinase proteins, their corresponding substrates, comprehensive kinase protein assay kits, stable cell lines, and biotinylated kinases, which are instrumental in investigating kinase-molecule interactions. The company also delivers a wide spectrum of scientific services. These services span from in-depth profiling and various cell-based kinase assays, including NanoBRET TE and ClariCELL intracellular assays, to protein detection and interaction analysis, live-cell kinase assays, crystallization, and weak affinity chromatography. Furthermore, they provide tyrosine kinase cell-based assay services and custom synthesis of ultra-pure proteins specifically for crystallography. Its therapeutic pipeline highlights several key investigational compounds. AS-0141, an orally administered small molecule designed to inhibit CDC7 kinase, is currently undergoing preclinical studies for cancer treatment. Another small molecule, AS-0871, is advancing through Phase 1 clinical trials for inflammatory and immune disorders. Moreover, AS-1763, an orally bioavailable, non-covalent inhibitor, is in preclinical assessment for chronic lymphocytic leukemia and other B-cell malignancies. Strategic collaborations have been established with leading pharmaceutical organizations, including Johnson & Johnson, Sierra Oncology, Sumitomo Dainippon Pharma, Gilead Sciences, and BioNova Pharmaceuticals.
Biotechnology
Kleo Pharmaceuticals, Inc. is a biotechnology company with headquarters in Japan and research operations in the United States, specializing in targeted immunotherapy platforms.
Biotechnology
LigaChem Biosciences is a clinical-stage biopharmaceutical company headquartered in Daejeon, South Korea. The company specializes in the discovery and development of novel therapeutics utilizing proprietary technology platforms such as antibody-drug conjugates. With decades of dedicated drug development experience, it drives global healthcare innovation through open collaboration.
Life Sciences
KisoJi Biotechnology Inc. is a drug discovery company headquartered in Montreal, Canada, utilizing a proprietary antibody discovery platform to create next-generation antibody drugs.
Similar biotech company
OmniAb, Inc. is an American biotechnology firm focused on pioneering therapeutic antibody discovery. The company provides a sophisticated platform that allows its industry partners to access a broad spectrum of antibody repertoires and advanced screening techniques, thereby facilitating the development of next-generation treatments. Central to the OmniAb platform is the unique biological capability of proprietary genetically engineered animals, such as OmniRat, OmniChicken, and OmniMouse. These animals are modified to produce human-sequence antibodies, simplifying the creation of human therapeutic candidates. Additionally, OmniAb offers specialized technologies like OmniFlic (a transgenic rat) and OmniClic (a transgenic chicken), which address the requirements for bispecific antibody applications via a common light chain method, as well as OmniTaur, which leverages the distinct structural properties of cow antibodies for challenging targets. The company was founded in 2012 and is based in Emeryville, California.
Biotechnology
AbbraTech Holdings LLC operates a platform technology focused on recombinant antibody discovery, engineering, and validation. The company targets human diseases such as cancer, immune disorders, and viral infections by developing antibodies for difficult-to-reach drug targets through its proprietary Epivolve technology.
Similar biotech company
Nanjing Leads Biolabs Co., Ltd. is a biotechnology firm currently in the clinical development phase, dedicated to the global discovery, progression, and eventual market launch of innovative antibody-based medications. The company's therapeutic endeavors concentrate on various critical illnesses, including cancerous growths, autoimmune disorders, and other serious medical conditions. A prominent product in its development pipeline is LBL-024, a bispecific antibody engineered to target PD-L1 and 4-1BB, specifically for the treatment of extra-pulmonary neuroendocrine carcinoma. Other significant compounds under development include LBL-034, LBL-033, and LBL-007. Nanjing Leads Biolabs also leverages its proprietary LeadsBody platform, which focuses on CD3 T-cell engagers that have demonstrated promising anti-tumor effects and safety in preliminary studies, as well as the X-body platform, which specializes in 4-1BB/PD-L1 bispecific antibodies. Beyond these, the company is actively researching antibody treatments for oncological, autoimmune, and infectious diseases, and is also engaged in establishing tumor immunoassays. Established in 2012, its primary operations are based in Nanjing, China.
Biotechnology
Cime Therapeutics Inc. is a chemistry-first company that provides an automated synthesis platform integrating artificial intelligence and machine learning for drug discovery. The company serves the pharmaceutical and biotechnology sectors by producing novel therapeutic molecules, such as small molecules, molecular glues, and covalent compounds, at high speed and scale.
Similar biotech company
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of カイオム・バイオサイエンス and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for カイオム・バイオサイエンスand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →